CA2450787C - Combinaison d'ingredients actifs pour substance pharmacologique toxicomanogene ou therapie contre les substances intoxicantes - Google Patents

Combinaison d'ingredients actifs pour substance pharmacologique toxicomanogene ou therapie contre les substances intoxicantes Download PDF

Info

Publication number
CA2450787C
CA2450787C CA002450787A CA2450787A CA2450787C CA 2450787 C CA2450787 C CA 2450787C CA 002450787 A CA002450787 A CA 002450787A CA 2450787 A CA2450787 A CA 2450787A CA 2450787 C CA2450787 C CA 2450787C
Authority
CA
Canada
Prior art keywords
pharmacologically acceptable
derivatives
active ingredient
acceptable salts
single dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002450787A
Other languages
English (en)
Other versions
CA2450787A1 (fr
Inventor
Joachim Moormann
Hermann Mucke
Klaus Opitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HF Arzneimittelforschung GmbH and Co KG
Original Assignee
HF Arzneimittelforschung GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HF Arzneimittelforschung GmbH and Co KG filed Critical HF Arzneimittelforschung GmbH and Co KG
Publication of CA2450787A1 publication Critical patent/CA2450787A1/fr
Application granted granted Critical
Publication of CA2450787C publication Critical patent/CA2450787C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

L'invention concerne une association de principes actifs composée d'au moins un modulateur du système cholinergique et d'au moins une substance d'action anti-excitatrice. Cette association est destinée au traitement médicamenteux d'une intoxication à des substances entraînant une dépendance ou à des stupéfiants, notamment l'alcoolisme.
CA002450787A 2001-06-18 2002-06-15 Combinaison d'ingredients actifs pour substance pharmacologique toxicomanogene ou therapie contre les substances intoxicantes Expired - Fee Related CA2450787C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10129265.1 2001-06-18
PCT/EP2002/006630 WO2002102388A2 (fr) 2001-06-18 2002-06-15 Association de principes actifs destinee au traitement medicamenteux d'une intoxication a des substances entrainant une dependance ou a des stupefiants

Publications (2)

Publication Number Publication Date
CA2450787A1 CA2450787A1 (fr) 2002-12-27
CA2450787C true CA2450787C (fr) 2009-06-02

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002450787A Expired - Fee Related CA2450787C (fr) 2001-06-18 2002-06-15 Combinaison d'ingredients actifs pour substance pharmacologique toxicomanogene ou therapie contre les substances intoxicantes

Country Status (28)

Country Link
US (1) US20040192683A1 (fr)
EP (1) EP1397138B1 (fr)
JP (1) JP2005500298A (fr)
KR (1) KR20040010744A (fr)
CN (1) CN1527711A (fr)
AR (1) AR034493A1 (fr)
AT (1) ATE286397T1 (fr)
AU (1) AU2002323873B2 (fr)
BR (1) BR0211008A (fr)
CA (1) CA2450787C (fr)
CZ (1) CZ299951B6 (fr)
DE (2) DE10129265A1 (fr)
EA (1) EA006647B1 (fr)
ES (1) ES2236551T3 (fr)
HK (1) HK1063292A1 (fr)
HU (1) HUP0400865A3 (fr)
IL (2) IL159345A0 (fr)
MX (1) MXPA03011825A (fr)
MY (1) MY129726A (fr)
NO (1) NO20035458D0 (fr)
NZ (1) NZ529944A (fr)
PL (1) PL367207A1 (fr)
PT (1) PT1397138E (fr)
SK (1) SK287180B6 (fr)
TW (1) TWI325320B (fr)
UA (1) UA76753C2 (fr)
WO (1) WO2002102388A2 (fr)
ZA (1) ZA200309232B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006121560A2 (fr) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Procedes et compositions pour le traitement des pathologies associees au systeme nerveux central
EP2316437B1 (fr) * 2005-05-13 2014-07-30 Alza Corporation Système d'administration de médicaments multicouche avec protection contre le flux de matériaux du réservoir
CN102516508A (zh) 2005-09-01 2012-06-27 三菱化学株式会社 聚酯颗粒的多段固相缩聚方法
WO2007035941A2 (fr) * 2005-09-23 2007-03-29 Alza Corporation Systeme d'administration transdermique de galantamine
PT2395990E (pt) 2009-02-12 2015-02-09 Univ Indiana Res & Tech Corp Material e métodos de tratamento de transtornos do desenvolvimento incluindo autismo comórbido e idiopático
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
MX346203B (es) 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
TWI618536B (zh) * 2010-12-03 2018-03-21 歐瑞根治療有限公司 於納曲酮療法中增加藥物生物可利用性
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
TWI678202B (zh) * 2016-12-14 2019-12-01 陸汝斌 組合物用於製備治療酒癮或酒精濫用之藥物的用途
BR112020003375A2 (pt) 2017-08-24 2020-08-25 Adamas Pharma, Llc composições de amantadina, preparações das mesmas, e métodos de uso
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (fr) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
KR100352212B1 (ko) * 1994-10-21 2003-04-18 자노케미아 파마조이티카 악티엔게젤샤프트 4a,5,9,10,11,12-헥사히드로-6H-벤조푸로[3a,3,2-ef][2]벤즈아제핀유도체의제조방법
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (fr) * 1998-03-26 1999-09-29 Lipha Combinaison pharmaceutique d'un antagoniste opioide et d'un modulateur du complexe récepteur de NMDA, utilisée dans le traitement de la dépendance à l'alcool ou de la toxicomanie
JP2002512214A (ja) * 1998-04-17 2002-04-23 ケネス カリー， 代謝生成物産生グルタミン酸レセプターアンタゴニストとしてのキュバン誘導体およびそれらの調製プロセス
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit

Also Published As

Publication number Publication date
CZ299951B6 (cs) 2009-01-07
SK15652003A3 (sk) 2004-04-06
SK287180B6 (sk) 2010-02-08
MXPA03011825A (es) 2005-03-07
CZ20033390A3 (en) 2004-03-17
WO2002102388A2 (fr) 2002-12-27
DE50201958D1 (de) 2005-02-10
PL367207A1 (en) 2005-02-21
EP1397138B1 (fr) 2005-01-05
WO2002102388A3 (fr) 2003-09-18
CN1527711A (zh) 2004-09-08
TWI325320B (en) 2010-06-01
IL159345A (en) 2009-02-11
HK1063292A1 (en) 2004-12-24
ZA200309232B (en) 2004-07-21
MY129726A (en) 2007-04-30
AU2002323873B2 (en) 2006-11-16
EP1397138A2 (fr) 2004-03-17
ES2236551T3 (es) 2005-07-16
AR034493A1 (es) 2004-02-25
KR20040010744A (ko) 2004-01-31
JP2005500298A (ja) 2005-01-06
US20040192683A1 (en) 2004-09-30
BR0211008A (pt) 2004-10-26
IL159345A0 (en) 2004-06-01
EA006647B1 (ru) 2006-02-24
HUP0400865A3 (en) 2011-03-28
UA76753C2 (uk) 2006-09-15
DE10129265A1 (de) 2003-01-02
NO20035458D0 (no) 2003-12-08
EA200400041A1 (ru) 2004-04-29
ATE286397T1 (de) 2005-01-15
PT1397138E (pt) 2005-04-29
HUP0400865A2 (hu) 2004-07-28
NZ529944A (en) 2007-02-23
CA2450787A1 (fr) 2002-12-27

Similar Documents

Publication Publication Date Title
CA2450787C (fr) Combinaison d'ingredients actifs pour substance pharmacologique toxicomanogene ou therapie contre les substances intoxicantes
AU2005215376A1 (en) Dopamine-agonist combination therapy with sedatives for improving sleep quality
JP2002532393A (ja) エキソ−ｒ−メカミラミン製剤および治療におけるその使用
JP2009517393A (ja) 不安症の治療方法
CA2985305C (fr) Combinaisons d'opioides et de n-acylethanolamines
ZA200404053B (en) Use of desoxypeganine for treating clinical depression.
AU2002354856B2 (en) Active substance combination for medicamentous therapy of nicotine dependency
WO1998005208A1 (fr) Procede de traitement de la consommation abusive de substances psychoactives
ZA200507213B (en) Combination of desoxypeganine and mecamylamine forthe treatment of alcohol abuse
AU2002325209B2 (en) Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
JP2007528891A (ja) 複合鎮痛剤医薬組成物
MXPA99001029A (en) Method for treating bipolar disorder

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed